Working with
patients in mind
Self Reflected by Greg Dunn
Our
Mission

We are dedicated to helping people suffering from neuropsychiatric disorders by developing a pipeline of psychedelic compounds into licensed pharmaceutical medicines.

Our
Research

Beckley Psytech’s innovative approach to helping patients in need is focused on developing psychedelic pharmacotherapy, psychotherapy and digital therapy to improve patient outcomes

More about our work

Compounds

Progressing innovative formulations and applications of psychedelic agents such as 5-MeO-DMT, psilocin and other compounds

Psychotherapy

Leveraging psychedelic-assisted therapy to target clinically meaningful improvements in a less time and resource intensive way

Digital

Digital tools are designed to deliver a holistic and differentiated solution to optimising patient outcomes

Lady Amanda Feilding
Our
Story

For our founders, Lady Amanda Feilding and Cosmo Feilding Mellen, psychedelic medicines have been a lifelong and intergenerational vocation.

More about us
Our
Leadership
Team
Cosmo Feilding Mellen
CEO
Dr. Steve Wooding
Director & Chief Scientific Officer
Dr. Frank Wiegand
Chief Medical Officer
Dr. Fiona Dunbar
Chief Medical Advisor
Becky Verity
Chief Commercial Officer
Michael Norris
Chief Financial Officer
Laura Trespidi
Chief Development Officer
Shlomi Raz
Director & Chief Business Officer
Tim Mason
Head of Deep Labs
Dr. Rob Conley
Chief Scientific Advisor
Matt Hartley
Chief of Staff & Head of Operations
News
and
views
Read all news
Contact
us

We’re building a pipeline of differentiated compounds to evaluate the potential of psychedelics and psychedelic-assisted psychotherapy in a variety of mental health and neurological disorders.

Get in touch to learn more about our work.

Thank you! Your submission has been received!
Oops! Something went wrong while submitting the form.